Syed Kazmi is President and Chief Executive officer of Jubilant Therapeutics Inc., a subsidiary of Jubilant Life Sciences Ltd. Jubilant Therapeutics is a US based innovative biopharmaceutical company developing breakthrough therapies for treating unmet medical need in serious diseases such as cancer.
Previously Syed worked as the Vice President and Global Head of Oncology Business Development & Licensing at Novartis, leading all BD&L efforts for Novartis Oncology including Search & Evaluation, Transactions, Due Diligence and Alliance Management. Prior to Novartis, Syed worked as the Executive Director of Business Development at Amgen, responsible for corporate mergers and acquisitions, global licensing and strategic collaborations; he also served as the Head of International Business Development.
Prior to joining Amgen in 2012, Syed served as Vice President and Head, Business Development & Strategic Planning, at Ligand Pharmaceuticals. Syed also worked for Johnson & Johnson as Principal Scientist in the R&D organization. Syed has a Ph.D. in Life Sciences (Biochemistry) and an executive MBA.
Previously Syed worked as the Vice President and Global Head of Oncology Business Development & Licensing at Novartis, leading all BD&L efforts for Novartis Oncology including Search & Evaluation, Transactions, Due Diligence and Alliance Management. Prior to Novartis, Syed worked as the Executive Director of Business Development at Amgen, responsible for corporate mergers and acquisitions, global licensing and strategic collaborations; he also served as the Head of International Business Development.
Prior to joining Amgen in 2012, Syed served as Vice President and Head, Business Development & Strategic Planning, at Ligand Pharmaceuticals. Syed also worked for Johnson & Johnson as Principal Scientist in the R&D organization. Syed has a Ph.D. in Life Sciences (Biochemistry) and an executive MBA.
Speaking In
[Available On-Demand]
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective…